<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)
COPLEY PHARMACEUTICAL, INC.
---------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
--------------------------------------
(Title of Class of Securities)
21745K-10-1
---------------
(CUSIP Number)
Julie K. Chapin Esq. Harry R. Benz
Associate General Counsel Hoechst Corporation
Hoechst Celanese Corporation Route 202-206
Route 202-206 P.O Box 2500
P.O. Box 2500 Somerville, NJ 08876-1258
Somerville, NJ 08876-1258 (908) 231-2281
(908) 231-2689
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
September 11, 1996
---------------------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Check the following box if a fee is being paid with this statement [ ].
<PAGE>
CUSIP No. 217445k-10=1 2
- --------------------------------------------------------------------------------
1) Name of Reporting Person and its Hoechst Corporation
I.R.S. Identification Number 22-1862783
- --------------------------------------------------------------------------------
2) Check the Appropriate Box if (a) [X]
a Member of a Group (b) [ ]
- --------------------------------------------------------------------------------
3) SEC Use Only
- --------------------------------------------------------------------------------
4) Source of Funds Not applicable
- --------------------------------------------------------------------------------
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
- --------------------------------------------------------------------------------
6) Citizenship or Place of Organization Delaware
- --------------------------------------------------------------------------------
Number of 7) Sole Voting Power 9,934,100
Shares
Beneficially ----------------------------------------------------
Owned by
Each 8) Shared Voting Power 0
Reporting
Person With ----------------------------------------------------
9) Sole Dispositive Power 9,934,100
----------------------------------------------------
10) Shared Dispositive Power 0
- --------------------------------------------------------------------------------
11) Aggregate Amount Beneficially Owned
by Each Reporting Person 9,934,100
- --------------------------------------------------------------------------------
12) Check Box If the Aggregate Amount
in Row (11) Excludes Certain Shares [ ]
- --------------------------------------------------------------------------------
13) Percent of Class Represented
by Amount in Row (11) 52.9%
- --------------------------------------------------------------------------------
14) Type of Reporting Person CO
<PAGE>
CUSIP No. 2174445k-10-1 3
- --------------------------------------------------------------------------------
1) Name of Reporting Person and its HCCP Acquisition Corporation
I.R.S. Identification Number 22-3277537
- --------------------------------------------------------------------------------
2) Check the Appropriate Box if (a) [X]
a Member of a Group (b) [ ]
- --------------------------------------------------------------------------------
3) SEC Use Only
- --------------------------------------------------------------------------------
4) Source of Funds Not applicable
- --------------------------------------------------------------------------------
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
- --------------------------------------------------------------------------------
6) Citizenship or Plan of Organization Delaware
- --------------------------------------------------------------------------------
Number of 7) Sole Voting Power 9,934,100
Shares
Beneficially --------------------------------------------
Owned by
Each 8) Shared Voting Power 0
Reporting
Person With --------------------------------------------
9) Sole Dispositive Power 9,934,100
--------------------------------------------
10) Shared Dispositive Power 0
- --------------------------------------------------------------------------------
11) Aggregate Amount Beneficially Owned
by Each Reporting Per 9,934,100
- --------------------------------------------------------------------------------
12) Check Box If the Aggregate Amount
in Row (11) Excludes Certain Shares [ ]
- --------------------------------------------------------------------------------
13) Percent of Class Represented
by Amount in Row (11) 52.9%
- --------------------------------------------------------------------------------
14) Type of Reporting Person CO
<PAGE>
This Statement on the Schedule 13D (the "Schedule 13D") with respect to
the Common Stock of Copley Pharmaceutical, Inc. (the "Issuer"), is filed jointly
by Hoechst Corporation, a Delaware Corporation ("Parent"), and HCCP Acquisition
Corporation ("Acquisition"). Parent and Acquisition hereby amend their
Statement on Schedule 13D with respect to the Common Stock of Issuer.
ITEM 4. PURPOSE OF TRANSACTION
- ------------------------------
Item 4 is hereby amended to add the following:
Ken E. Starkweather, a senior financial manager of Parent's subsidiary,
Hoechst Marion Roussel, Inc. ("HMRI"), has left his position as Director of
Procurement for US operations of HMRI to become Vice President - Finance of the
Issuer. Parent reviews continuously its investments, including its investment in
the Issuer, and may, depending upon its evaluation of the business and prospects
of the Issuer and on future developments and general market and economic
conditions, as well as opportunities available to Parent or Acquisition, and
subject to existing or future contractual restrictions, limitations, or
requirements, at any time determine to seek to influence management of, or
seek control of, the Issuer, or cease such influence or control, or increase or
decrease, or cease to increase or decrease, or dispose of its holdings of
securities of the Issuer.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
- ----------------------------------------
EXHIBIT A Agreement to File Jointly dated October 9, 1996, by and
between Parent ant Acquisition.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
HOECHST CORPORATION
----------------------------------
By: David A. Jenkins
Vice President, General Counsel &
Secretary
Date: October 9, 1996
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
HCCP ACQUISITION CORPORATION
----------------------------------
By: Rebecca R. Tilden
Secretary
Date: October 9, 1996
<PAGE>
Exhibit A to Schedule 13D
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached Schedule
13D, as well as each subsequent amendment, is filed on behalf of each of us.
HOECHST CORPORATION
----------------------------------
By: David A. Jenkins
Vice President, General Counsel &
Secretary
Date: October 9, 1996
HCCP ACQUISITION CORPORATION
----------------------------------
By: Rebecca R. Tilden
Secretary
Date: October 9, 1996
